Loading
A phase 2 trial of Domvanalimab, Zimberelimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Arcus Biosciences, Inc., active and no longer recruiting.
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer is a phase 2 interventional study registered as NCT04736173 by Arcus Biosciences, Inc., with 169 participants enrolled, started 2021-02-08 and due to reach its primary completion in 2027-05. Interventions recorded: Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed. Conditions listed: Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Domvanalimab, Zimberelimab, Pemetrexed, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Domvanalimab, Zimberelimab, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.